Hims & Hers Health, Inc. has introduced a compounded oral semaglutide pill that uses the same active ingredient as Novo Nordisk’s Wegovy. The new product is priced at $49 for the first month and $99 for each subsequent month, offering a substantially lower cost alternative to the branded Wegovy, which starts at $149 per month for initial doses and rises to $299 for higher doses.
The launch comes amid a regulatory backdrop that includes a September 2025 FDA warning to Hims & Hers for misleading claims about compounded semaglutide and ongoing threats of legal action from Novo Nordisk over what it calls “illegal mass compounding.” The SAFE Drugs Act of 2025, which seeks to tighten oversight of compounded GLP‑1 medications, adds further uncertainty to the product’s long‑term viability.
Investors reacted negatively to the announcement, reflecting concerns that a lower‑priced compounded pill could erode the margins of Novo Nordisk and Eli Lilly, while Hims & Hers was viewed favorably for its ability to capture price‑sensitive customers in the rapidly expanding obesity‑treatment market.
Hims & Hers’ recent financial performance underscores the strategic importance of the launch. In Q3 2025 the company reported revenue of nearly $600 million, up 49% year‑over‑year, and net income of $16 million. Adjusted EBITDA reached $78 million, and the company raised its full‑year 2025 Adjusted EBITDA guidance to $307 million–$317 million. Earlier in the year, Q1 2025 revenue hit $586 million, up 111% YoY, with net income of $49.5 million and Adjusted EBITDA of $91.1 million. The new pill is expected to accelerate growth in the weight‑loss segment, which has become a key driver of the company’s overall expansion.
CEO Andrew Dudum emphasized that the launch is part of a broader strategy to “put the power of choice back into the hands of the individual.” CFO Yemi Okupe highlighted the company’s “strong, profitable growth” and the role of infrastructure investments in scaling personalized care across multiple specialties.
Strategically, the compounded semaglutide pill positions Hims & Hers as a direct competitor to Novo Nordisk and Eli Lilly, leveraging its large fulfillment footprint and telehealth platform to offer a lower‑cost alternative. The move also signals the company’s intent to deepen its personalization moat, but it faces regulatory headwinds from FDA scrutiny and potential legislative restrictions under the SAFE Drugs Act. The product’s success will hinge on balancing regulatory compliance with the demand for affordable weight‑loss options.
The launch marks a significant step in Hims & Hers’ push into the GLP‑1 market, potentially expanding its customer base and revenue streams. However, the company must navigate ongoing regulatory challenges and competitive pressure from established players, which could impact the long‑term sustainability of the compounded product line.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.